// App-Quantinova.ai

PD5-03 : Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Researchers

Presenter

  • Sherene Loi

Principal Investigators

  • Oleg Lipatov

  • Seock-Ah Im

  • Anthony Goncalves

  • Javier Cortes

  • Keun S Lee

  • Peter Schmid

  • Laura Testa

  • Isabell Witzel

  • Shoichiro Ohtani

  • Nicholas Turner

  • Stefania Zambelli

  • Nadia Harbeck

  • Fabrice Andre

  • Rebecca Dent

  • LingKang Huang

  • Jaime Mejia

  • Vassiliki Karantza

  • Roberto Salgado

Medical Centers

  • Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia

  • Dana-Farber Cancer Institute, Boston, MA

  • Republican Clinical Oncology Dispensary, Republic of Tatarstan, Russian Federation

  • Peter Macallum Cancer Institute, Melbourne, Australia

  • Institut Paoli-Calmettes, Marseille, France

  • IOB Institute of Oncology, Quiron Group; Vall d'Hebron Institute of Oncology (VHIO), Madrid & Barcelona, Spain

  • National Cancer Center, Goyang-si, Korea, Republic of.

  • Barts Cancer Institute, Centre for Experimental Cancer Medicine, London, United Kingdom

  • Instituto do Cancer de Sao Paulo, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan

  • Royal Marsden Hospital National Health Service Trust, London, United Kingdom

  • San Raffaele Scientific Institute, Milan, Italy

  • Breast Center, University of Munich, Munich, Germany

  • Faculte de Medicine Paris-Sud XI, Gustave Roussy, Villejuif, France

  • University of Toronto, Toronto, ON, Canada

  • Merck & Co., Inc., Kenilworth, NJ

Locations

  • Australia

  • United States

  • Russia

  • France

  • Spain

  • Republic of South Korea

  • United Kingdom

  • Brazil

  • Germany

  • Japan

  • Italy

  • Canada

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Brain metastasis

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

  • tumor-infiltrating lymphocytes

Drug/Treatment

  • Pembrolizumab

  • Capecitabine

  • Gemcitabine

  • Vinorelbine

  • Eribulin

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02555657

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved